GSA Capital Partners LLP Acquires Shares of 10,729 Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

GSA Capital Partners LLP bought a new position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,729 shares of the company’s stock, valued at approximately $268,000.

Several other hedge funds and other institutional investors also recently modified their holdings of KNSA. CWM LLC boosted its stake in Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the period. nVerses Capital LLC bought a new position in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $80,000. Lazard Asset Management LLC purchased a new position in Kiniksa Pharmaceuticals during the first quarter valued at approximately $71,000. Ashton Thomas Private Wealth LLC bought a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth approximately $100,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Kiniksa Pharmaceuticals by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company’s stock worth $195,000 after purchasing an additional 3,076 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Jefferies Financial Group assumed coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 target price for the company. Evercore ISI raised their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals has an average rating of “Buy” and a consensus target price of $36.60.

Insider Activity

In related news, insider John F. Paolini sold 60,692 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the sale, the insider now owns 52,038 shares of the company’s stock, valued at $1,359,232.56. This represents a 53.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Eben Tessari sold 17,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the completion of the transaction, the chief operating officer now owns 109,975 shares of the company’s stock, valued at approximately $2,955,028.25. This represents a 13.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 112,692 shares of company stock worth $2,950,315 in the last three months. Company insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Trading Up 0.9 %

Shares of KNSA opened at $21.28 on Friday. The company has a market cap of $1.54 billion, a price-to-earnings ratio of -152.00 and a beta of 0.35. The business’s fifty day simple moving average is $24.29 and its two-hundred day simple moving average is $22.88. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $15.52 and a 12 month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The company had revenue of $112.21 million for the quarter, compared to analysts’ expectations of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s quarterly revenue was up 67.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.20) earnings per share. As a group, research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.